octreotide acetate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 141 Diseases   27 Trials   27 Trials   1501 News 


«1234567891011»
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Trial primary completion date:  Acromegaly Combination Treatment Study (clinicaltrials.gov) -  Mar 9, 2022   
    P=N/A,  N=76, Recruiting, 
    Trial primary completion date: Dec 2021 --> Jul 2022
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Journal:  Determination of neuron-specific enolase in patients with midgut-type tumour treated with somatostatin analogues. (Pubmed Central) -  Feb 23, 2022   
    Mutations in HADH may be associated with abnormal neurodevelopmental outcomes despite diazoxide-responsiveness. In our study, we observed that NSE concentration values were significantly higher among patients with NET midgut type tumour with histological grade G2 and in patients with 25% liver involvement and progression of the disease process.
  • ||||||||||  Journal:  The future of somatostatin receptor ligands in acromegaly. (Pubmed Central) -  Feb 19, 2022   
    Pasireotide, a second-generation SRL, shows higher efficacy with respect to both biochemical control and tumor shrinkage but has a worse safety profile...New formulations of available SRLs, such as oral, subcutaneous depot and nasal octreotide, may improve patients' adherence to treatment and quality of life since there will be more options available that better suit each patient. Finally, new drugs, such as paltusotine, somatropin, ONO-5788 and ONO-ST-468, may improve treatment adherence and present higher efficacy than currently available drugs.
  • ||||||||||  tolvaptan / Generic mfg.
    Clinical, Review, Journal:  Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature. (Pubmed Central) -  Feb 15, 2022   
    On the contrary, tolvaptan is authorized worldwide and has received more attention in the last years, even if its clinical use is widely limited by aquaresis tolerability. The aim of this review is to investigate the advantages and drawbacks of somatostatin analogues and tolvaptan in the treatment of ADPKD.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Review, Journal:  A challenging TSH/GH co-secreting pituitary adenoma with concomitant thyroid cancer; a case report and literature review. (Pubmed Central) -  Jan 18, 2022   
    We report the first aggravated case of TSH/GH co-secreting pituitary tumor after total thyroidectomy for concomitant multifocal PTMC. Deferring of thyroid surgery until the TSHoma is well controlled may be the optimal therapeutic strategy in patients with TSHoma and coexistent thyroid cancer; ablative thyroid surgery may result in catastrophic pituitary tumor growth.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal:  Targeted radionuclide therapy: an emerging field in solid tumours. (Pubmed Central) -  Jan 14, 2022   
    Recent research has demonstrated and consolidated the use of TRNT against well established targets in neuroendocrine tumours and prostate cancer. The identification of new promising molecular targets for TRNT, will further expand the theranostic applications of radionuclides in the field of nuclear medicine.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Clinical data, Journal:  Self-Administration of Long-Acting Somatostatin Analogues in NET Patients-Does It Affect the Clinical Outcome? (Pubmed Central) -  Dec 27, 2021   
    The method of administration of long-acting SSA injection performed by professional medical staff vs. self-injection of the drug may significantly affect the risk of NET progression. The unequivocal confirmation of such a relationship requires further observation.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Journal:  Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands. (Pubmed Central) -  Dec 18, 2021   
    Patients included in this analysis were enrolled in a randomized phase 3 study, were biochemically-controlled (an IGF-1 < 1.3 × the upper limit of normal [ULN] and average GH < 2.5 ng/ml) and receiving SRL injections for ≥6 months with a stable dose of either long-acting octreotide or lanreotide monotherapy for ≥4 months...GI side effects and ISRs were also common. This study highlights the significant disease burden that still persists for patients with acromegaly that have achieved biochemical control with the use of injectable SRLs.
  • ||||||||||  Lutathera (lutetium Lu 177 dotatate) / Novartis, Sutent (sunitinib) / Pfizer, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal, HEOR:  Use of [Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study. (Pubmed Central) -  Dec 17, 2021   
    A three-state partitioned survival model was developed to perform a cost-utility analysis of [Lu]Lu-DOTA-TATE versus standard of care (high dose Octreotide LAR), everolimus and sunitinib...In P-NETs, the ICER of [Lu]Lu-DOTA-TATE compared to SoC was £22,146 (€23,101) or £28,038 (€29,251) dependent on matched population, and £21,827 (€22,766) and £15,768 (€16,445) compared to everolimus and sunitinib, respectively. At a willingness to pay threshold of £30,000, [Lu]Lu-DOTA-TATE is likely to be a cost-effective treatment option for GI-NET and P-NET patients versus relevant treatment comparators (NHS perspective).
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Journal:  Gastrointestinal Bleeding Rates in Left Ventricular Assist Device Population Reduced with Octreotide Utilization. (Pubmed Central) -  Nov 29, 2021   
    The most common dose of long-acting octreotide was 30 mg every 28 days...Of the 13 patients who rebled after initiation of octreotide, the frequency of events decreased by 2.6 bleeds per patient per year (4.8 vs. 2.2; p = 0.043). In high-risk patients who have failed conventional therapy, octreotide can be useful for the prevention of recurrent GIB.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal:  Medical Therapy of Acromegaly in Germany 2019 - Data from the German Acromegaly Registry. (Pubmed Central) -  Nov 7, 2021   
    This randomized, blinded study evaluating pt comfort found minimal pain with OCT and LAN and no significant differences in pain scores. The majority of German acromegalic patients receiving medical therapy are controlled according to normal IGF-1 levels.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal:  The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system. (Pubmed Central) -  Nov 6, 2021   
    To be cost-effective as initial therapy, the price of lanreotide would need to be lowered by 48% to 95% or 27% to 86% to reach ICERs of $100,000/QALY or $150,00/QALY, respectively. The study showed that octreotide LAR treatment could be a risk factor in addition to known factors for the development of gastritis in patients with acromegaly.
  • ||||||||||  Lutathera (lutetium Lu 177 dotatate) / Novartis
    Trial completion date, Metastases:  NETTER-2: Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (clinicaltrials.gov) -  Oct 22, 2021   
    P3,  N=222, Recruiting, 
    The present model is the first to describe the multiple-peak absorption pattern observed after octreotide LAR administration and may be useful to provide insights and validate hypotheses regarding release from PLGA-based formulations. Trial completion date: Dec 2026 --> Oct 2027
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy:  Tolvaptan-Octreotide LAR Combination in ADPKD (clinicaltrials.gov) -  Oct 6, 2021   
    P2,  N=20, Active, not recruiting, 
    Cette efficacité doit cependant étre confirmée dans un essai thérapeutique. Recruiting --> Active, not recruiting | Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Enrollment change:  Acromegaly Combination Treatment Study (clinicaltrials.gov) -  Sep 28, 2021   
    P=N/A,  N=76, Recruiting, 
    Long-acting lanreotide was significantly superior versus long-acting octreotide in the rate of acromegaly remission, which does not correspond with clinical trials. N=51 --> 76
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Aortic Dissection In A Patient With Metastatic Carcinoid Tumor (Exhibit Hall) -  Sep 25, 2021 - Abstract #ASA2021ASA_4360;    
    Patient was on outpatient octreotide LAR to control carcinoid tumor symptoms; medical oncologist and leading experts were consulted to develop safe anesthetic plan to avoid and treat possible carcinoid crisis. Dissection repair with hemiarch replacement was successfully performed without intraoperative carcinoid crisis.
  • ||||||||||  leuprorelin depot / Generic mfg.
    Journal:  Physical-chemical characterization of octreotide encapsulated in commercial glucose-star PLGA microspheres. (Pubmed Central) -  Sep 16, 2021   
    Sandostatin LAR (SLAR) is an injectable long-acting release (LAR) microsphere formulation for octreotide based on a biodegradeable glucose star copolymer of d,l-lactic and glycolic acids (PLGA-glu), which is primarily used for the treatment of patients with acromegaly...Leuprolide is considered as a cationic peptide competitor for octreotide-PLGA interactions and its presence in the release medium resulted in more continuous octreotide release from SLAR, which was linearly correlated with the mass loss from the polymer (i.e., an indication of erosion-controlled release)...This salt is expected to catalyze octreotide acylation and extend peptide release beyond that is driven by erosion-control. The characterization studies of physicochemical properties of SLAR described here could be useful for development and regulatory evaluation of generic octreotide microspheres as well as new polymer formulations in which the polymer strongly interacts with encapsulated peptides.
  • ||||||||||  metformin / Generic mfg., everolimus / Generic mfg., octreotide acetate / Generic mfg.
    Enrollment closed, Enrollment change, Trial completion date, Combination therapy, Metastases:  MetNET1: Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs (clinicaltrials.gov) -  Sep 9, 2021   
    P2,  N=26, Active, not recruiting, 
    He was successfully treated with octreotide therapy. Recruiting --> Active, not recruiting | N=43 --> 26 | Trial completion date: Jun 2021 --> Oct 2021
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Review, Journal:  Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. (Pubmed Central) -  Jul 14, 2021   
    Despite widespread use of octreotide LAR, several key challenges exist with the current depot-based treatment paradigm...The purpose of this review is to explore all these issues and to re-establish a rationale for the IR formulation, particularly with respect to novel use cases and its use during the COVID-19 pandemic. IMPLICATIONS FOR PRACTICE: There is a need to re-evaluate the role of IR octreotide in combination with depot therapy to provide consistent bioavailability and better control of carcinoid syndrome symptoms.